Termeer

During meetings with Genzyme shareholders planned for next week, this person said, Mr. Termeer is expected to offer "an updated view of what 2011 will look like."

Genzyme Will Explore 'White Knight' Gina Chon 2010

Furthermore, Mr. Termeer could receive another $62.8 million from payments related to a contingent value right that is connected to each share sold to Sanofi in the deal.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011

Sanofi said its chief executive, Chris Viehbacher, met with Genzyme CEO Henri Termeer on September 20 in an attempt to "advance discussions" but that the meeteing "proved unproductive."

Sanofi Launches Genzyme Bid Jeanne Whalen 2010

Last week Termeer said that a fairer value for Genzyme shares would be closer to $80, its price before the 2008 financial crisis and the company's subsequent manufacturing problems.

Sanofi Launches Genzyme Takeover Battle By GREG KELLER 2010

At least that is the hope of Genzyme Chief Executive Henri Termeer.

Genzyme Plays for Time John Jannarone 2010

Once the deal closes, probably early in the second quarter, Mr. Termeer would receive salary, bonus and benefits totaling about $12.5 million, according to a regulatory filing.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011

That payment assumes that he leaves the company after the deal closes, something that Mr. Termeer has discussed in the past.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011

Although Mr. Termeer oversaw decades of growth at Genzyme, his reign hasn't been rosy in recent years as manufacturing issues, product shortages and regulatory intervention have damaged the company's business.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011

NEW YORK— Genzyme Corp. Chief Executive Henri Termeer could receive more than $220 million after the biotech company's sale to French drug maker Sanofi-Aventis SA.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011

Mr. Termeer, who is Dutch-born, joined Genzyme in 1983, about two years after its founding, and built up a successful business focused on treating rare genetic disorders with high-priced medicines.

Genzyme's CEO Could Get Big Payment Thomas Gryta 2011